MITF抗体

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using MITF mouse mAb against PANC-1 (1) and A549 (2) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of Hela cells using MITF mouse mAb (green) and negative control (red).    

  
  

The Microphthalmia-associated transcription factor (MITF) is a key regulator of melanocyte development, differentiation, and survival. It belongs to the basic helix-loop-helix leucine zipper (bHLH-Zip) family of transcription factors and controls the expression of genes critical for melanin synthesis, such as tyrosinase (TYR), tyrosinase-related protein 1 (TYRP1), and PMEL. MITF also plays roles in other cell types, including osteoclasts, mast cells, and retinal pigment epithelium, influencing processes like bone resorption and immune response. Dysregulation of MITF is linked to diseases such as melanoma, Waardenburg syndrome (a genetic disorder affecting pigmentation and hearing), and osteoporosis.

MITF antibodies are essential tools in research and diagnostics, used to detect MITF protein expression and localization via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). These antibodies help identify MITF isoforms (e.g., MITF-M in melanocytes, MITF-A in other tissues) and assess its role in cellular pathways or disease mechanisms. In clinical settings, MITF antibodies aid in diagnosing melanocytic tumors, as MITF is a sensitive marker for melanoma. However, cross-reactivity with related transcription factors (e.g., TFE3. TFEB) requires careful validation. Studies using MITF antibodies have advanced understanding of its dual role as an oncogene and tumor suppressor, depending on cellular context, highlighting its therapeutic potential in cancer and genetic disorders.